Cardiovascular
Percutaneous Coronary Intervention
0
Pipeline Programs↗
14
Active Trials↗
9
Companies Involved↗
Percutaneous Coronary Intervention is an early-stage landscape with 0 programs across 9 companies. The most active players are Merck & Co., Egetis Therapeutics, Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
78
clinical trials
Completed43 · 55%
Unknown status11 · 14%
Recruiting9 · 12%
Terminated9 · 12%
Active, not recruiting3 · 4%
Not yet recruiting2 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
78 trials
Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
Recruiting·—·Phase 4·NCT06916520·300 enrolled
Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06463808·100 enrolled
Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary Intervention
Completed·—·Phase 3·NCT04538534·1,500 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)